Scarica l'app Stockscreener
8.79
1.57%
-0.14
Dopo l'orario di chiusura:
8.92
0.13
+1.48%
Zevra Therapeutics Inc Borsa (ZVRA) Ultime notizie
Zevra Therapeutics Appoints New CFO - Intellectia AI
Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer - citybiz
Zevra Therapeutics Names Justin Renz CFO - marketscreener.com
25-year biopharma finance leader Justin Renz joins Zevra as CFO - Stock Titan
Royce & Associates LP Takes Position in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Zevra Therapeutics (ZVRA) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Zevra Therapeutics, Inc. to Announce Fourth Quarter and Full Year 2025 Results on March 9, 2026 - Quiver Quantitative
Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call - Yahoo Finance
How Zevra Therapeutics Inc. (ZVRA) Affects Rotational Strategy Timing - Stock Traders Daily
Zevra Therapeutics, Inc. (ZVRA) Investor Outlook: Uncovering a Potential 148% Upside in the Biotech Sector - DirectorsTalk Interviews
ZVRA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Is Zevra Therapeutics (ZVRA) Pricing Reflect Its Strong DCF Upside Potential? - Yahoo Finance
Rare-disease biotech Zevra heads to Miami for Citizens Life Sciences Conference - Stock Titan
RSI Check: Will Zevra Therapeutics Inc benefit from geopolitical trendsEarnings Summary Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
ZVRAZevra Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Zevra Therapeutics, Inc. (ZVRA) Investor Outlook: Exploring A Potential 153.59% Upside - DirectorsTalk Interviews
Can Zevra Therapeutics Inc. sustain earnings growthJuly 2025 Opening Moves & AI Forecast for Swing Trade Picks - mfd.ru
Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - TradingView
(ZVRA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Delaware Chancery Court Holds that Grant of Security Interest is a “Transfer” – Commave v. Zevra | Insights - Mayer Brown
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Short Interest Update - MarketBeat
Earnings Beat: Can Zevra Therapeutics Inc maintain sales growthJuly 2025 Selloffs & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Can Zevra Therapeutics Inc. stock double in the next yearJuly 2025 Gainers & AI Powered Market Entry Strategies - mfd.ru
What is the next catalyst for Zevra Therapeutics Inc.Weekly Stock Summary & Safe Entry Point Alerts - mfd.ru
Will Zevra Therapeutics Inc. benefit from geopolitical trendsWeekly Trade Analysis & Real-Time Buy Zone Alerts - mfd.ru
Zevra Therapeutics, Inc. (ZVRA) Stock Analysis: Unveiling a 168% Potential Upside in Biotechnology - DirectorsTalk Interviews
Neil F. McFarlane, Zevra Therapeutics president, sells $125k in shares - Investing.com Canada
Stock Analysis: What is the implied volatility of Zevra Therapeutics IncEarnings Growth Report & Technical Confirmation Alerts - baoquankhu1.vn
Zevra Therapeutics opens Nasdaq with bell ceremony - Traders Union
Zevra Therapeutics Rings the Opening Bell - Nasdaq
Responsive Playbooks and the ZVRA Inflection - Stock Traders Daily
Zevra Therapeutics, Inc. (ZVRA) Investor Outlook: Unpacking a 169.66% Potential Upside with Robust Revenue Growth - DirectorsTalk Interviews
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA in Patients with Neimann-Pick Disease Type C at the 22nd Annual WorthLDSymposium - marketscreener.com
ZVRA: Zevra Therapeutics Unveils Promising Data on Miplyffa at W - GuruFocus
Zevra Therapeutics Presents Positive Data on MIPLYFFA® for Niemann-Pick Disease Type C at WORLDSymposium™ 2026 - Quiver Quantitative
Zevra Therapeutics Presents Positive New Real-World Data on - GlobeNewswire
4 years of real-world data track MIPLYFFA in rare Niemann-Pick disease - Stock Titan
Zevra Therapeutics CEO McFarlane sells $853k in shares - Investing.com South Africa
Schafer Joshua, CCO of Zevra, sells $29,800 in ZVRA stock By Investing.com - Investing.com UK
Schafer Joshua, CCO of Zevra, sells $29,800 in ZVRA stock - Investing.com Nigeria
Zevra Therapeutics (NASDAQ:ZVRA) Insider Sells $29,801.25 in Stock - MarketBeat
Zevra Therapeutics (NASDAQ:ZVRA) Insider Sells $40,026.39 in Stock - MarketBeat
Neil Mcfarlane Sells 91,000 Shares of Zevra Therapeutics (NASDAQ:ZVRA) Stock - MarketBeat
Insider Selling: Zevra Therapeutics (NASDAQ:ZVRA) SVP Sells 1,750 Shares of Stock - MarketBeat
Zevra Therapeutics CEO McFarlane sells $853k in shares By Investing.com - Investing.com South Africa
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026 - The Manila Times
Published on: 2026-02-02 12:45:20 - baoquankhu1.vn
Portfolio Shifts: Can Zevra Therapeutics Inc maintain sales growthJuly 2025 Spike Watch & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Layoff Watch: Does Zevra Therapeutics Inc have declining or rising EPS2025 Growth vs Value & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Short Interest Down 32.5% in January - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):